Table 1.
Characteristic | RRSO Group (n = 509) |
Observation/Surveillance Group (n = 283) |
P | ||
---|---|---|---|---|---|
No. | % | No. | % | ||
Age at start of follow-up, years | |||||
Mean | 47.1 | 42.9 | < .001 | ||
Median | 45.3 | 38.8 | |||
Range | 31.1–79.0 | 30.0–87.8 | |||
Mutations | |||||
BRCA1 | 325 | 64 | 173 | 61 | .49 |
BRCA2 | 184 | 36 | 110 | 39 | |
Parous | 419 of 507 | 83 | 203 of 280 | 73 | .001 |
Prior oral contraceptive use | 342 of 481 | 71 | 178 of 253 | 70 | .86 |
Prior hormone replacement use | 56 of 488 | 11 | 18 of 267 | 7 | .040 |
Personal history of breast cancer | 303 | 60 | 133 | 47 | .001 |
Time to RRSO, months | |||||
Mean | 10.3 | — | |||
Median | 4.9 | — | |||
Range | 0.1–83.3 | — | |||
Follow-up, months | |||||
Mean | 40.3 | 37.6 | .15 | ||
Median | 34.8 | 30.1 | |||
Range | 6.0–114.6 | 6.2–119.3 |
Abbreviation: RRSO, risk-reducing salpingo-oophorectomy.